Skip to main content
Clinical Trials/NCT04365270
NCT04365270
Completed
Phase 3

The Antimicrobial Activity and Clinical Performance of Chitosan-modified Glass Ionomer: A Randomized Clinical Trial

Ain Shams University1 site in 1 country65 target enrollmentJanuary 15, 2019

Overview

Phase
Phase 3
Intervention
Glass Ionomer
Conditions
Reversible Pulpitis
Sponsor
Ain Shams University
Enrollment
65
Locations
1
Primary Endpoint
Antibacterial
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The study is a randomized clinical trial that assesses the clinical success and the antibacterial effect on carious dentine of glass ionomer when modified with Chitosan and/or Titanium dioxide nano particles vs the control group of modification with Chlorhexidine as control when used in primary molars

Detailed Description

Participants will be recruited from the acquitted to the clinic of pediatric dentistry department , Faculty of Dentistry of Ain Shams University. random allocation of the participants where indirect pulp capping is indicated so that modified Glass ionomer would be used as the filling material. partial removal of caries is done then caries sample would be taken and sent for a microbiological evaluation and then, cavity dimensions is recoded, finally placement of the modified glass ionomer in the prepared cavity. In a total period of 9 months the patients will be followed every 3 months for clinical evaluation and in the final visit the filling would be removed and another bacterial sample would be taken for comparison, then a permanent filling is placed.

Registry
clinicaltrials.gov
Start Date
January 15, 2019
End Date
January 5, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Omar Assem Hodhod

Principal Investigator,Teaching Assistant ,Dentist

British University In Egypt

Eligibility Criteria

Inclusion Criteria

  • The teeth will be primary molars selected from patients presented to the outpatient clinic that are
  • Healthy patients.
  • Age: 4-8 years.
  • Children having at least one primary molar with only occlusal caries having dentine lesions wide enough for the smallest excavator to enter (Ø=0.9 mm).

Exclusion Criteria

  • Teeth with pulp involvement, those suffering from pain, irreversible pulpits or pulp necrosis.
  • Children with systemic diseases.
  • Patients with history of active para-functional oral habits, xerostomia.
  • Patients who will have difficulties in cooperating.

Arms & Interventions

Glass ionomer

Stock powder and liquid Fuji IX from GC japan

Intervention: Glass Ionomer

Chitosan Glass ionomer

purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan. will be placed in the prepared cavity over the last layer of caries

Intervention: Glass Ionomer

Chitosan Glass ionomer

purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan. will be placed in the prepared cavity over the last layer of caries

Intervention: Chitosan Low Molecular Weight (20-200 Mpa.S)

Chitosan/Titanium dioxide nanoparticles Glass ionomer

The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid. The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries

Intervention: Glass Ionomer

Chitosan/Titanium dioxide nanoparticles Glass ionomer

The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid. The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries

Intervention: Chitosan Low Molecular Weight (20-200 Mpa.S)

Chitosan/Titanium dioxide nanoparticles Glass ionomer

The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid. The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries

Intervention: Titanium Dioxide

Chlorhexidine glass ionomer

Chlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v

Intervention: Glass Ionomer

Chlorhexidine glass ionomer

Chlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v

Intervention: Chlorhexidine Diacetate

Outcomes

Primary Outcomes

Antibacterial

Time Frame: 9 months

Dentin samples incubated on 2 culture mediums and total bacterial count by counting colony forming units will be counted. Higher number means Less antibacterial effect

Clinical performance

Time Frame: followup 9 months

"Modified United States Public Health Service Ryge Criteria" for Direct Clinical Evaluation and rating of Restoration.measuring color match, anatomic contour, marginal integrity, cavosurface marginal discoloration, secondary caries, surface texture, gross fracture. each outcome will be graded Alpha(A) for the highest score, Bravo(b) for moderate score, and Charlie(C) for the lowest score.

Study Sites (1)

Loading locations...

Similar Trials